IL6 and temporal arteritis: Tocilizumab (162 mg subcutaneous weekly), an interleukin-6 inhibitor, was successfully proven to be effective in GCA [24] and is available in the UK for use in aortitis in ‘relapsing and refractory cases’, following the failure of two conventional treatment strategies [25].